skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility

Review

(1598) Views  (529) Full article downloads

Authors: Vivencio Barrios, Carlos Escobar

Published Date May 2010 Volume 2010:3 Pages 11 - 19
DOI: http://dx.doi.org/10.2147/IBPC.S6636

Vivencio Barrios1, Carlos Escobar2

1Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain; 2Department of Cardiology, Hospital Infanta Sofia, Madrid, Spain

Abstract: Although reducing blood pressure is the most important approach to reduce cardiovascular outcomes in the hypertensive population, the majority of patients fail to attain the targets. Most patients with hypertension need at least 2 antihypertensive agents to achieve blood pressure goals. The 2007 European hypertension guidelines state that combined therapy is needed when monotherapy does not attain blood pressure objectives and as a first-line treatment in high-risk patients. This point has been reinforced in the 2009 update of the European guidelines. The advantages of combination therapy are well documented with the potential for increased antihypertensive efficacy as a result of different mechanisms of action, and a lower incidence of adverse effects because of the lower doses used and the possible compensatory responses. Moreover, the use of fixed dose combinations are specially recommended as they facilitate treatment compliance. The inhibition of the renin-angiotensin system appears to be very beneficial in the treatment of patients with hypertension along the cardiovascular continuum and the combination of a renin-angiotensin system inhibitor and a diuretic is particularly recommended. Many clinical trials have demonstrated the benefits of the fixed combination perindopril/indapamide in the treatment of hypertension. The aim of this manuscript is to update the published data on the efficacy and safety of this fixed combination.

Keywords: fixed dose, combination therapy, angiotensin-converting enzyme, diuretic






 

Other articles by Dr Vivencio Barrios



Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Perindopril: the evidence of its therapeutic impact in hypertension
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Study of pharmacokinetics and tissue distribution of liposomal brucine for dermal administration
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University